Marshall Edwards, Inc.(Nasdaq: MSHL) shares leaped 172.7% to $3.19, after it announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. Volume for the stock topped 2.5 million shares, dwarfing a daily average around 75,000.
The San Diego-based Marshall Edwards, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced in news release dated July 27 the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company’s investigational compound and lead mitochondrial inhibitor drug candidate, NV-344.
The publication, entitled “Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells,” is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal.
Previous studies conducted at Yale University showed that NV-128 is able to inhibit tumor growth in an ovarian cancer animal model without inducing significant toxicity, suggesting a sufficient therapeutic window that may allow compounds of this class to be safely administered to patients. Marshall Edwards plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the first quarter of 2012.
In the same release, company CEO Daniel Gold said, “This study exemplifies the importance of our ongoing collaboration with … Yale University as well as our continuing commitment to enhancing our pipeline of novel drug candidates.
“We are excited about the progress we are making with both of our lead candidates, NV-143 and NV-344, and look forward to reporting on their clinical development in the months ahead.” Gold concluded.
Marshall Edwards, Inc. is focused on the clinical development of novel anti-cancer therapeutics. The Company’s lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism.